| Trial name or title | Omega‐3 supplementation and attention‐deficit‐hyperactivity disorder (ADHD) |
| Methods | Randomised, placebo‐controlled trial |
| Participants | 40 children, 6 years to 13 years, diagnosed with ADHD will be randomised to consume either ALA (3 grams of ALA‐containing plant oil) or placebo for 2 months Inclusion criteria: ADHD diagnosis Exclusion criteria: any comorbidities, any medication or supplement use |
| Interventions | Dietary supplement: omega‐3 fatty acid alpha‐linolenic acid (ALA) Dietary supplement: placebo |
| Outcomes | Baseline and end assessments will include both ADHD‐related questionnaires and tests, and blood fatty acid composition |
| Starting date | April 2009 |
| Contact information | Gal Dubnov‐Raz The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer 52621, Israel Email: gal.dubnov‐raz@sheba.health.gov.il |
| Notes | Email sent 23 April 2012 to check on progress of study |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.